NCT05626517Not yet recruiting
JARVISDHL Screening Tools
Source: ClinicalTrials.gov · Last updated 23 Nov 2022 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The main purpose of this study is to pioneer an easy risk stratification tools, which is developed using novel artificial intelligence (AI) algorithms, that will be able to detect common and fatal heart diseases easily simply through a picture of the back of the eye, the retina. The retinal images will be analysed using a computer application with the risk stratification tool to predict health outcome of individual. The study also aims to correlate between clinical characteristics, lifestyle (eg. exercise, sleep, erectile dysfunction) and diet to retinal and coronary vasculature and clinical outcomes.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 2000 (estimated)
- First submitted
- 13 Sept 2022
- Start date
- 30 Jan 2023
- Primary completion date
- 30 Jun 2024
- Lead sponsor
- National Heart Centre Singapore
- Diseases
- Coronary artery disease
- NCT number
- NCT05626517
What you commit to
- Study type: Observational
- Planned participants: 2000
- From 30 Jan 2023 to the primary completion date, 30 Jun 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients with cardiac event (acute myocardial infarction, Stroke, heart failure, angina requiring hospitalization) and/or coronary revascularization (percutaneous coronary intervention (PCI) and/or coronary artery bypass grafting (CABG) prior to CTCA
- Patients with cardiac event (acute myocardial infarction, Stroke, heart failure, angina requiring hospitalization) and/or coronary revascularization (percutaneous coronary intervention (PCI) and/or coronary artery bypass grafting (CABG) prior to CTCA
Age
- Age \<21 years old
- Age \<21 years old
Other
- Patients whose informed consent was not obtained.
- Patient whose informed consent was not obtained.
Who the study is looking for
- 21 years of age or older
- Sufficient language skills in English or Chinese
- Provided informed consent
- Completed CTCA or CT CAC in the past 6 months.
- 21 years of age or older
- Sufficient language skills in English or Chinese
- Provided informed consent
- Patient diagnosed with Diabetes for more than or equal to 10 years.
Age in the registry: 21 years to 99 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| National Heart Centre Singapore Coordinator of this site? Confirm its status | Singapore | Singapore | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.